Compliance
503A vs 503B for GLP-1 Clinic Supply: 2026 Decision Guide
Choosing 503A vs 503B for GLP-1 clinic office use in 2026? Get the regulatory timeline, 2026 enforcement updates, and a decision framework for clinic owners.
The Catalog / The Resource LibraryFor clinic owners
Every decision worth getting right
Plain-English, operator-to-operator guidance on the decisions that trip up new and growing aesthetic and wellness practices — pharmacy, prescribers, capital equipment, compliance, and program launch. Each guide answers a question we field on a first call, in full, so you walk into the decision already knowing the traps.
Filter by topic
Devices
XTherma RF Device vs. Other Monopolar RF Platforms
Comparing the XTherma RF device to other monopolar RF platforms? Here’s the cost, clearance, and ROI framework clinic owners should run before signing.
Compliance
FDA Peptide Vote, July 2026: All 7 Results
Six recommended, one rejected — every tally from the July 23–24 advisory committee, plus the four things the vote does not mean for your practice.
Prescribers
Who Prescribes Compounded Medications?
Who writes the prescription, what 503A and 503B each ask of the prescriber, how medical direction differs from prescribing, why a standing order does not replace the exam — and what breaks when the prescriber is missing.
Pharmacy
How to Vet a Compounding Pharmacy
What to verify in public records before the first sales call, the questions in the order worth asking them, what a good answer sounds like next to an evasive one, and the terms worth walking away from. Names no pharmacy, ours included.
Reference
The Compounding Glossary
55 terms that appear in pharmacy agreements, board rules and vendor decks — 503A, 503B, beyond-use date, cGMP, HCT/P, CPOM — defined in plain English, with sources.
Pharmacy
503A vs 503B, in Plain English
How each pharmacy type works, when your clinic uses which, and what to verify before you partner — with FDA sources.
Prescribers
Get a Medical Director in All 50 States
What a doctor’s network provides, the ownership trap most contracts hide, what to verify before signing, and the 7–10 day path.
Biologics
Exosomes: The 2026 Compliance Picture
The FDA regulatory reality, the documentation to demand on every lot, sourcing red flags, and state variability — compliance-first.
Devices
Buy vs. Lease Your First Laser
Upfront vs monthly economics, the utilization break-even that actually decides it, and the questions to ask any distributor.
Programs
Adding GLP-1 — In the Right Order
Prescriber, pharmacy, platform, patients — the sequence that works, the compounded-medication reality, and the 6-week model.
Not sure which question comes first? The Growth Scorecard asks six questions about your practice and returns the order the decisions actually want to be made in — before you read a word further.
Take the Growth ScorecardNext move15–20 minutes
Have a question these guides didn’t cover?
A 15-20 minute call covers whatever your practice is deciding right now — pharmacy, prescriber coverage, devices, or a program launch — with someone who’s vetted the options on behalf of clinics for years. No cost, no obligation.
Educational information for licensed medical providers and practice owners. Everything in this library is educational and is not legal, medical, or financial advice; requirements vary by state and license type. Compounded medications are not FDA-approved, and biologic and exosome products are not FDA-approved to diagnose, treat, cure, or prevent any disease. No patient outcome, revenue, or income is claimed or guaranteed. Consult your own advisors for decisions affecting your practice.